Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status

Cancer Gene Therapy

Volumn 16, Issue 11, 2009, Pages 832-840

  Ma, G ^a,b   Kawamura, K ^a   Li, Q ^a   Suzuki, N ^b   Liang, M ^c   Namba, M ^d   Shimada, H ^a   Tagawa, M ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Shanghai Sunway Biotech Co Ltd   (China)

^d Niimi University   (Japan)

Author keywords

Adenovirus; CAR; Esophageal carcinoma; P53

Indexed keywords

ADENOVIRUS VECTOR; CD51 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; PROTEIN P53;

ADENOVIRUS; ADENOVIRUS INFECTION; ARTICLE; CARCINOMA CELL; CELL IMMORTALIZATION; CELL MUTANT; CONTROLLED STUDY; CYTOTOXICITY; ESOPHAGUS CARCINOMA; FIBROBLAST; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION; WILD TYPE;

ADENOVIRIDAE; BLOTTING, WESTERN; CARCINOMA; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAV; RECEPTORS, VIRUS; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 70350090278     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.21     Document Type: Article

References (27)

1. Siersema PD, van Hillegersberg R. Treatment of locally advanced esophageal cancer with surgery and chemoradia-tion. Curr Opin Gastroenterol 2008; 24: 535-540.
2. Edelman J, Edelman J, Nemunaitis J. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Curr Opin Mol Ther 2003; 5: 611-617.
3. Shimada H, Shimizu T, Ochiai T, Liu TL, Sashiyama H, Nakamura A et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001; 31: 597-604.
4. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006; 97: 554-561.
5. Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H et al. p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 2007; 6: 1478-1482.
6. Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther 2004; 11: 643-664.
7. Shayakhmetov DM, Papayannopoulou T, Stamatoyanno-poulos G, Lieber A. Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
8. Pong RC, Roark R, Ou JY, Fan J, Stanfield J, Frenkel E et al. Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoes-trogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application. Cancer Res 2006; 66: 8822-8828.
9. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1995; 8: 889-897.
10. St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther 2000; 7: 749-756.
11. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
12. Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 1996; 7: 1683-1691.
13. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645.
14. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998; 72: 9479-9490.
15. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
16. Fushimi K, Iijima M, Gao C, Kondo T, Tsuji T, Hashimoto T et al. Transformation of normal human fibroblasts into immortalized cells with the mutant p53 gene and X-rays. Int J Cancer 1997; 70: 135-140.
17. Compton T. An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection. J Virol 1993; 67: 3644-3648. (Pubitemid 23143748)
18. Nielsen LL, Maneval DC. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52-63.
19. Quist SR, Wang-Gohrke S, Kohler T, Kreienberg R, Runnebaum IB. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther 2004; 11: 547-554.
20. Tango Y, Taki M, Shirakiya Y, Ohtani S, Tokunaga N, Tsunemitsu Y et al. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells. Cancer Sci 2004; 95: 459-463.
21. Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 2000; 92: 1002-1008.
22. Nemunaitis JJ, Sobol RE, Clayman G, Hamm J, Goodwin W. Evaluation of functional p53 biomarker profiles predicts efficacy of adenoviral p53 gene therapy (Advexin) in patients with recurrent squamous cells carcinoma of the head and neck (SCCHN). Mol Ther 2008; 16: S156.
23. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothe-lial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001; 61: 6952-6957.
24. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL et al. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). Cancer Gene Ther 2000; 7: 530-536.
25. Pong RC, Lai YJ, Chen H, Okegawa T, Frenkel E, Sagalowsky A et al. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 2003; 63: 8680-8686.
26. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005; 8: 61-74.
27. Bruning A, Runnebaum IB. CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFa, and TGFb. Gene Ther 2003; 10: 198-205.